Telithromycin: Difference between revisions

Telithromycin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Latest revision as of 01:40, 20 February 2025

An article about the antibiotic Telithromycin

Telithromycin is a ketolide antibiotic used to treat certain types of bacterial infections. It is derived from the macrolide antibiotic erythromycin and is specifically designed to overcome resistance mechanisms that affect macrolides.

Mechanism of Action[edit]

Telithromycin works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby blocking the translocation of peptides. This action is similar to that of macrolides, but telithromycin has a higher affinity for the ribosomal subunit, which makes it effective against certain macrolide-resistant strains.

Clinical Uses[edit]

Telithromycin is primarily used to treat community-acquired pneumonia, acute bacterial sinusitis, and acute exacerbations of chronic bronchitis. It is effective against a range of Gram-positive bacteria, including Streptococcus pneumoniae and Staphylococcus aureus.

Side Effects[edit]

Common side effects of telithromycin include nausea, vomiting, diarrhea, and dizziness. Serious side effects can include hepatotoxicity, visual disturbances, and loss of consciousness. Due to these potential risks, its use is often limited to cases where other antibiotics are not suitable.

Resistance[edit]

Resistance to telithromycin can occur through various mechanisms, including mutations in the ribosomal RNA and efflux pump activation. However, its design allows it to evade some of the common resistance mechanisms that affect other macrolides.

Regulatory Status[edit]

Telithromycin was approved by the Food and Drug Administration (FDA) in 2004. However, due to concerns about its safety profile, its use has been restricted in some countries.

Related pages[edit]

Telithromycin

@@ Line 1: / Line 1: @@
-Telithromycin
+{{Short description|An article about the antibiotic Telithromycin}}
+{{Drugbox
+| verifiedfields = changed
+| verifiedrevid = 477002123
+| image = Telithromycin.svg
+| image2 = <!-- Another image if available -->
+}}
-An oral antibiotic in restricted use.
+'''Telithromycin''' is a [[ketolide]] antibiotic used to treat certain types of [[bacterial infections]]. It is derived from the macrolide antibiotic [[erythromycin]] and is specifically designed to overcome resistance mechanisms that affect macrolides.
-{{intro}}
+==Mechanism of Action==
-Telithromycin is a ketolide, a novel form of macrolide antibiotic that is recommended for treatment of community acquired pneumonia.  Telithromycin was approved for use in the United States in 2004 and subsequently linked to several cases of severe drug induced liver injury.
+Telithromycin works by inhibiting bacterial [[protein synthesis]]. It binds to the 50S subunit of the bacterial [[ribosome]], thereby blocking the translocation of peptides. This action is similar to that of macrolides, but telithromycin has a higher affinity for the ribosomal subunit, which makes it effective against certain macrolide-resistant strains.
-{{moa}}
+==Clinical Uses==
-Telithromycin (tel ith" roe mye' sin) is a ketolide antibiotic, a novel form of macrolide antibiotic that is used to treated community acquired pneumonia.  Telithromycin differs from erythromycin by several substitutions that render it less susceptible to erythromycin-resistant strains of bacteria.  Telithromycin is active against staphylococci, streptococci, S. pneumoniae, Haemophilus spp., Moraxella catarrhalis, mycoplasma, chlamydia and Legionella.
+Telithromycin is primarily used to treat [[community-acquired pneumonia]], [[acute bacterial sinusitis]], and [[acute exacerbations of chronic bronchitis]]. It is effective against a range of [[Gram-positive bacteria]], including [[Streptococcus pneumoniae]] and [[Staphylococcus aureus]].
-{{fda}}
+==Side Effects==
-Telithromycin was first approved for use in the United States in 2004 and initially had several clinical indications including sinusitis and bronchitis.  Currently, because of the potential of serious side effects, the only approved indication for telithromycin is moderate-to-severe community acquired pneumonia due to sensitive organisms.
+Common side effects of telithromycin include [[nausea]], [[vomiting]], [[diarrhea]], and [[dizziness]]. Serious side effects can include [[hepatotoxicity]], [[visual disturbances]], and [[loss of consciousness]]. Due to these potential risks, its use is often limited to cases where other antibiotics are not suitable.
-{{dose}}
+==Resistance==
-Telithromycin is available in oral forms under the trade name Ketek in tablets of 300 mg (for reduced dosing in patients with renal disease) and 400 mg.  The recommended dosage is 800 mg once daily for 7 to 10 days.
+Resistance to telithromycin can occur through various mechanisms, including mutations in the ribosomal RNA and efflux pump activation. However, its design allows it to evade some of the common resistance mechanisms that affect other macrolides.
-{{se}}
+==Regulatory Status==
-Telithromycin is generally well tolerated, but side effects can include nausea, abdominal pain, diarrhea, dyspepsia, headache, dizziness and rash.
+Telithromycin was approved by the [[Food and Drug Administration]] (FDA) in 2004. However, due to concerns about its safety profile, its use has been restricted in some countries.
-{{macrolides}}
-{{coststubd}}
+==Related pages==
+* [[Antibiotic resistance]]
+* [[Macrolide antibiotics]]
+* [[Bacterial infections]]
+[[Category:Antibiotics]]
+[[Category:Ketolides]]
+<gallery>
+File:Telithromycin.svg|Telithromycin
+</gallery>